CN103517918A - 拮抗性dr3配体 - Google Patents

拮抗性dr3配体 Download PDF

Info

Publication number
CN103517918A
CN103517918A CN201280011136.1A CN201280011136A CN103517918A CN 103517918 A CN103517918 A CN 103517918A CN 201280011136 A CN201280011136 A CN 201280011136A CN 103517918 A CN103517918 A CN 103517918A
Authority
CN
China
Prior art keywords
antibody
seq
univalent
fab
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280011136.1A
Other languages
English (en)
Chinese (zh)
Inventor
M.D.安德森
P.L.诺尔德拜
K.克贾尔加尔德
S.N.格雷尔
A.格鲁勒
J.布查尔特
H.S.安德森
S.帕德贾尔
J.卡斯特鲁普
K.哈亚坎斯森
L.霍努姆
B.弗里伊德里奇森
D.鲍恩斯加尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN103517918A publication Critical patent/CN103517918A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280011136.1A 2011-03-01 2012-03-01 拮抗性dr3配体 Pending CN103517918A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11156416.7 2011-03-01
EP11156416 2011-03-01
US201161448827P 2011-03-03 2011-03-03
US61/448,827 2011-03-03
PCT/EP2012/053539 WO2012117067A1 (en) 2011-03-01 2012-03-01 Antagonistic dr3 ligands

Publications (1)

Publication Number Publication Date
CN103517918A true CN103517918A (zh) 2014-01-15

Family

ID=44210048

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280011136.1A Pending CN103517918A (zh) 2011-03-01 2012-03-01 拮抗性dr3配体

Country Status (12)

Country Link
US (4) US9737612B2 (https=)
EP (1) EP2681237A1 (https=)
JP (1) JP6215056B2 (https=)
KR (1) KR20140043720A (https=)
CN (1) CN103517918A (https=)
BR (1) BR112013022052A2 (https=)
CA (1) CA2828464A1 (https=)
IL (1) IL227535A0 (https=)
MX (1) MX2013009859A (https=)
RU (1) RU2013141079A (https=)
WO (1) WO2012117067A1 (https=)
ZA (1) ZA201306110B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536548A (zh) * 2014-04-28 2017-03-22 国家生物技术研究所公司 Dr3变体及其用途
CN107001462A (zh) * 2014-04-04 2017-08-01 协和发酵麒麟株式会社 激动活性降低的抗死亡受体3(dr3)拮抗性抗体
CN111808183A (zh) * 2020-07-25 2020-10-23 北京吉尔麦迪生物医药科技有限公司 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
CN116223818A (zh) * 2023-05-09 2023-06-06 四川大学华西医院 Dr3蛋白检测试剂在制备筛查aecopd的试剂盒的用途及筛查aecopd的试剂盒

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2972330A4 (en) * 2013-03-15 2016-10-26 Alder Biopharmaceuticals Inc PROTOCOL FOR THE IDENTIFICATION AND ISOLATION OF ANTIGEN-SPECIFIC B-CELLS AND FOR THE PREPARATION OF ANTIBODIES FOR DESIRED ANTIGENES
WO2015036553A1 (en) 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
US9416197B2 (en) 2013-11-01 2016-08-16 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
EP3572502B1 (en) * 2017-01-20 2023-01-11 Kyoto University Method for producing cd8alpha +beta + cytotoxic t cells
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
US20250249278A1 (en) 2022-04-14 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
EP4501966A4 (en) * 2022-06-17 2025-10-22 Selecxine Inc ANTIBODY SPECIFICALLY BINDING TO HUMAN DR3 AND ITS USE
CN120399074B (zh) * 2023-06-02 2025-12-30 安徽金百奥生物科技有限公司 一种与人dr3胞外域高亲和力的纳米抗体
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
GB202315963D0 (en) 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
WO2025158389A1 (en) 2024-01-24 2025-07-31 Shattuck Labs, Inc. Antibodies that bind tnfrsf25

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064465A1 (en) * 1999-04-22 2000-11-02 Human Genome Sciences, Inc. Death domain containing receptors
WO2001035995A2 (en) * 1999-11-19 2001-05-25 Tittle Thomas V Tr3-specific binding agents and methods for their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
CN101070344A (zh) 1998-04-30 2007-11-14 泰诺士公司 G－csf受体兴奋剂抗体及其筛选方法
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US7148061B2 (en) 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
WO2002040680A2 (en) 2000-11-17 2002-05-23 The Burnham Institute Death domain proteins
US20040234524A1 (en) 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20090317388A1 (en) * 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
JP5164167B2 (ja) * 2005-08-30 2013-03-13 ユニバーシティー オブ マイアミ 免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
US20110195048A1 (en) 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064465A1 (en) * 1999-04-22 2000-11-02 Human Genome Sciences, Inc. Death domain containing receptors
WO2001035995A2 (en) * 1999-11-19 2001-05-25 Tittle Thomas V Tr3-specific binding agents and methods for their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LENG WEN 等: "TL1A-induced NF-kB Activation and c-IAP2 Production Prevent DR3-mediated Apoptosis in TF-1 Cells", 《JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 278, no. 40, 25 July 2003 (2003-07-25), pages 39251 - 39258 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001462A (zh) * 2014-04-04 2017-08-01 协和发酵麒麟株式会社 激动活性降低的抗死亡受体3(dr3)拮抗性抗体
CN106536548A (zh) * 2014-04-28 2017-03-22 国家生物技术研究所公司 Dr3变体及其用途
CN111808183A (zh) * 2020-07-25 2020-10-23 北京吉尔麦迪生物医药科技有限公司 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
CN116223818A (zh) * 2023-05-09 2023-06-06 四川大学华西医院 Dr3蛋白检测试剂在制备筛查aecopd的试剂盒的用途及筛查aecopd的试剂盒

Also Published As

Publication number Publication date
ZA201306110B (en) 2014-04-30
EP2681237A1 (en) 2014-01-08
BR112013022052A2 (pt) 2016-11-22
US9737612B2 (en) 2017-08-22
US8765130B2 (en) 2014-07-01
JP2014509325A (ja) 2014-04-17
JP6215056B2 (ja) 2017-10-18
US20130330360A1 (en) 2013-12-12
RU2013141079A (ru) 2015-04-10
IL227535A0 (en) 2013-09-30
MX2013009859A (es) 2014-02-28
US20130336984A1 (en) 2013-12-19
US20170305994A1 (en) 2017-10-26
US20140294853A1 (en) 2014-10-02
WO2012117067A1 (en) 2012-09-07
CA2828464A1 (en) 2012-09-07
KR20140043720A (ko) 2014-04-10
US9713644B2 (en) 2017-07-25

Similar Documents

Publication Publication Date Title
CN103517918A (zh) 拮抗性dr3配体
CN105001333B (zh) 抗人nkg2d抗体及其用途
US10472414B2 (en) Antibodies specific to pyroglutamated Aβ
KR102483016B1 (ko) ＦｃＲｎ 항체 및 이의 사용 방법
BR112021004723A2 (pt) anticorpos de receptor anti-il4 para uso veterinário
EP3322726B1 (en) Antibodies that bind to sortilin and inhibit the binding of progranulin
CN110997712A (zh) 特异性结合pd-1的抗体及其使用方法
CN109071648A (zh) 抗il-2抗体及其组合物和用途
CN109476742A (zh) Tl1a抗体及其用途
CN110407941A (zh) Cd39的高亲和力抗体及其用途
US20210009706A1 (en) Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use Thereof
US12590149B2 (en) Antibody and bispecific antibody targeting LAG-3 and use thereof
US12331113B2 (en) Anti-human NR1 antibody derivative
AU2017205343A1 (en) Self-crosslinking antibodies
US20190023788A1 (en) Agents, uses and methods for treatment
US20200131263A1 (en) Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN106661104B (zh) 抗硬骨素抗体、其抗原结合片段及其医药用途
CN108473549A (zh) 单链gitr受体激动剂蛋白
WO2021112185A1 (ja) 抗ｇｄｆ１５抗体
RU2847361C1 (ru) Антитела против klk5
AU2012222342A1 (en) Antagonistic DR3 ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140115